CTRI/2022/12/048283
Recruiting
Phase 3
A multi-center randomized controlled trial to compare the efficacy, safety, and tolerability of high dose, short course Primaquine–A pilot study
ICMR National Institute of Malaria Research0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ICMR National Institute of Malaria Research
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.P. vivax (asexual) malaria monoinfection confirmed by microscopy on a thin and thick blood smear
- •2\.Age 16 years and over of either gender.
- •3\.Fever \> 37\.5°C axillary, or a history of fever within 48 hours
- •4\.Female patients of child\-bearing potential are included if they are non\-lactating and willing to use contraceptive methods during the study period. Non\-child bearing potential defined as:
- •4\.1 post\-menopausal (12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH \>40 mIU/mL), pre\-menopausal and has had a hysterectomy or a bilateral oophorectomy (removal of the ovaries) or a bilateral tubal ligation with medical report verification or,
- •4\.2 Child\-bearing potential, has a negative urine pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and for a period of 90 days after stopping study drug:
- •4\.2\.1 Use of oral contraceptive, either combined or progesterone alone (if no contraindications to oral contraceptives exist).
- •4\.2\.2 Barrier contraceptive if oral contraceptives are contraindicated
- •4\.2\.3 Use of an intrauterine device.
- •5\.Willing to give informed consent.
Exclusion Criteria
- •1\.Patients with G6PD activity less than 30% of the adjusted male median (AMM), tested by UV spectrophotometry.
- •2\.Patients with mixed infection with P. vivax and P. falciparum (e.g. identified by Giemsa\-stained smear or rapid diagnostic test).
- •3\.Patient with body weight less than 40 kg.
- •4\.Severe P. vivax malaria defined as per Indian National Guidelines criteria (Appendix I).
- •5\.Haemoglobin \<8 g/dl to be measured by Hb auto analyser.
- •6\.Cannot tolerate oral treatment
- •7\.History of haemolytic anaemia or methemoglobinemia or blood transfusion within 90 days
- •8\.Pregnant and lactating females.
- •9\.Known allergy to chloroquine, primaquine or any other related drugs.
- •10\.Evidence of gastro\-intestinal dysfunction that could alter absorption or motility (e.g., diarrhoea defined as \>3 episodes of watery stools in the previous 24 h or patients who have had three episodes of vomiting within 24 h prior to screening).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Autoinflation for Aboriginal and Torres Strait Islander Children with OME (middle ear infection)Otitis Media with EffusionHealth of Aboriginal ChildrenEar - Other ear disordersInfection - Other infectious diseasesACTRN12617001652369Western Sydney University150
Completed
Phase 3
A multicentre randomised controlled trial to compare the efficacy of ex-vivo oxygenated hypothermic machine perfusion with non-oxygenated hypothermic machine perfusion of kidneys from donors older than 50 years of age and donated after circulatory death.Endstage renal failureRenal insufficiency1002914910038365NL-OMON44723niversity of Oxford93
Completed
Not Applicable
A proactive and structured telephone based intervention to reduce carer burden and depression among carers of cancer patientsCarer burdenDepression/anxietyQuality of lifeUnmet needsHealth literacyCancer - Any cancerMental Health - DepressionMental Health - AnxietyACTRN12613000731796Deakin University230
Recruiting
Not Applicable
A multicentre randomized controlled trial to improve the AccUracy of Referrals to the emerGency departmEnt of patieNts with chesT pain by using the modified HEART score in Emergency Medical Transport(URGENT 2.0)NL-OMON55210Viecuri Medisch Centrum voor Noord-Limburg852
Recruiting
Not Applicable
A multicenter randomized controlled trial to evaluate overall morbidity after total minimally invasive esophagectomy versus hybrid esophagectomyC15.9Oesophagus, unspecifiedDRKS00027927Klinik für Allgemeine, Viszeral- und Transplantationschirurgie Universitätsklinikum Tübingen152